Adamis Pharmaceuticals
2658 Del Mar Heights Road
Suite 555
Del Mar
California
92014
United States
181 articles with Adamis Pharmaceuticals
-
Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update
3/16/2023
Adamis Pharmaceuticals Corporation announced financial results for the full year ended December 31, 2022, and provided an update on recent corporate developments.
-
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update
3/14/2023
Adamis Pharmaceuticals Corporation announced that it will host an investor conference call on Thursday, March 16, 2023 at 2:00 p.m. PT to discuss its financial and operating results for the fourth quarter and full year 2022 as well as provide a corporate update.
-
Adamis Pharmaceuticals Announces $3.0 Million Registered Direct Offering
3/14/2023
Adamis Pharmaceuticals Corporation announced it has entered into a securities purchase agreement with a single, healthcare-focused institutional investor for the purchase and sale of 16,500,000 shares of its common stock and pre-funded warrants to purchase up to 7,500,000 shares of common stock, together with warrants to purchase up to 48,000,000 shares of common stock, at a combined purchase price of $0.125 per share and accompanying warrants, pursuant to a registered direct offering.
-
Adamis Pharmaceuticals and DMK Pharmaceuticals Announce Agreement and Plan of Merger
2/27/2023
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) and DMK Pharmaceuticals, Corp. today announced that the companies have entered into an Agreement and Plan of Merger and Reorganization (the “Agreement”).
-
Nasdaq Grants Adamis Pharmaceuticals’ Request for Extension to Comply with Continued Listing Requirements
2/22/2023
Adamis Pharmaceuticals Corporation announced that the Nasdaq Hearings Panel has granted the Company’s request for continued listing on Nasdaq, pursuant to an extension through June 26, 2023 to evidence compliance with the $1.00 bid price requirement and its continued compliance with all other applicable criteria for continued listing on the Nasdaq Capital Market.
-
Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
11/14/2022
Adamis Pharmaceuticals Corporation reported financial results for the third quarter of 2022 and provided an update on recent corporate developments.
-
Adamis Pharmaceuticals Schedules Third Quarter 2022 Financial Results Conference Call and Corporate Update
11/7/2022
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it will host an investor conference call on Monday, November 14, 2022 at 2:00 p.m. PT to discuss its financial and operating results for the third quarter 2022 as well as provide a corporate update.
-
Adamis Announces Review of Strategic Alternatives
10/3/2022
Adamis Pharmaceuticals Corporation announced that following the recently announced halting of the Company’s Phase 2/3 clinical trial examining the effects of Tempol in high risk subjects with early COVID-19 infection, it has initiated a process to explore a range of strategic and financing alternatives focused on maximizing stockholder value.
-
Alaunos Therapeutics, Satsuma Pharmaceuticals, NeuroSense, Emyria and more reported updates in solid tumors, migraine, ALS and MDMA drug discovery.
-
Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects
9/21/2022
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the third planned interim analysis of the Phase 2/3 clinical trial examining the effects of Tempol in high risk subjects with early COVID-19 infection.
-
Adamis Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects
9/12/2022
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the Company’s ongoing U.S. Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19 has reached the initial planned enrollment of 248 subjects.
-
High-Dose Naloxone Product Giving People Hope to Help Combat Growing Opioid Overdose Trend
8/31/2022
On International Overdose Awareness Day, community encouraged to learn about additional treatment options to help save lives.
-
Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders
8/12/2022
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its 2022 Annual Meeting of Stockholders (“Annual Meeting”) was convened, as scheduled.
-
Adamis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8/10/2022
Adamis Pharmaceuticals Corporation reported financial results for the second quarter of 2022 and provided an update on recent corporate developments.
-
Adamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results Conference Call and Corporate Update
8/8/2022
Adamis Pharmaceuticals Corporation today announced that it will host an investor conference call on Wednesday, August 10, 2022 at 1:30 p.m. Pacific Time to discuss its financial and operating results for the second quarter 2022 as well as provide a corporate update.
-
Leading Independent Proxy Advisory Firm ISS Recommends Adamis Pharmaceuticals’ Stockholders Vote FOR Critical Proposals at Upcoming Annual Meeting
7/29/2022
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that Institutional Shareholder Services Inc. ("ISS"), a leading independent proxy advisory firm, has recommended the Company’s stockholders vote FOR Proposal #2 and Proposal #3 on the agenda at the upcoming Annual Meeting of Stockholders (the “Annual Meeting”) on August 12, 2022.
-
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19Interim DSMB review expected in late September
7/29/2022
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the Company’s ongoing U.S. Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19.
-
Adamis Pharmaceuticals Issues Letter to Stockholders
7/21/2022
Adamis Pharmaceuticals Corporation issued the following letter to stockholders from Chief Executive Officer David J. Marguglio.
-
Adamis Appoints Vickie Reed to Board of Directors
5/26/2022
Adamis Pharmaceuticals Corporation announced the appointment of Vickie Reed as a new director and member of the company’s board of directors.
-
Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth
5/18/2022
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory diseases, today announced a leadership transition plan to support its efforts to unlock long-term growth and value creation opportunities: